Composition: Each tablet contains Nelfinavir Mesylate equivalent to Nelfinavir IP 250 mg
Dosage form: Tablet (coating not specified)
Usage: Combination treatment of HIV-1 infection; not HIV prevention
Category: HIV Anti Viral Drugs
Therapeutic category: Antiviral / HIV-1 Protease Inhibitor
SKU: Nelfinavir Tablets
Categories: Pharmaceutical Exporter India, Pharmaceutical Formulations India, WHO GMP Certified Formulations
Nelfinavir Tablets IP is listed in our pharmaceutical product portfolio for business-to-business enquiries. Product-specific formulation details, available strengths, dosage form, pack configuration and supply terms should be confirmed against the current product specification before ordering.
For distributor, wholesaler, hospital procurement and export enquiries, please request the applicable product specifications, batch documentation, shelf-life information, packaging options and regulatory documents. Availability and documentation depend on the product and destination market.
Manufacturer: Healthy Life Pharma Pvt. Ltd. (WHO-GMP status requires verification)
Exporter: Healthy Inc (Star Export House status requires verification)
Nelfinavir is an HIV-1 protease inhibitor used with other antiretroviral medicines to treat HIV-1 infection. It reduces viral replication but does not cure HIV or prevent infection when used alone. Treatment choice depends on current guidelines, resistance, interactions and availability; nelfinavir is an older agent and is not generally a preferred modern first-line option.
The supplied product composition confirms Nelfinavir Mesylate equivalent to Nelfinavir IP 250 mg per tablet. A 625 mg presentation appears in the supplied descriptive text but has no corresponding confirmed composition and must be verified separately.
| Product name | Nelfinavir Tablets |
|---|---|
| Active ingredient | Nelfinavir mesylate equivalent to Nelfinavir IP 250 mg per tablet |
| Confirmed strength | 250 mg |
| Dosage form | Tablet; coating not specified in supplied formula |
| Pharmacopoeial standard | IP (as supplied); USP/BP claims require verification |
| Therapeutic class | Antiretroviral / HIV-1 protease inhibitor |
| CAS number | 159989-65-8 (nelfinavir mesylate; verify material specification) |
| SKU | Nelfinavir Tablets |
| Shelf life / packaging | Confirm against approved stability data and commercial label |
Label note: The submitted formula does not confirm a blue film coating, bottle count or 625 mg strength.
High drug loading, consistent blend uniformity, compression performance and dissolution are important formulation considerations. Any claims about high-shear granulation, particular binders, film coating, desiccant use or a proprietary manufacturing process require batch documentation and validation before publication. Product packaging should be based on demonstrated stability.
Testing should follow the applicable registered IP monograph and approved product specifications, including identification, assay, uniformity of dosage units, dissolution, impurities and stability where required. Specific acceptance limits and claimed 24–36-month shelf life cannot be verified from the supplied composition. Quality and impurity-control claims require supporting certificates and stability records.
Nelfinavir inhibits HIV protease, preventing processing of viral polyproteins into functional proteins and resulting in immature viral particles. It is used as a component of combination antiretroviral therapy for HIV-1, where locally approved. Regimens are selected by an HIV specialist using current treatment recommendations, resistance results and individual factors.
Important: Nelfinavir is not an HIV vaccine, pre-exposure prophylaxis (PrEP), or a stand-alone medicine to prevent HIV acquisition.
Confirm destination-country marketing authorization, current availability, prescription restrictions, approved indications and antiretroviral procurement rules before promotion or export. CTD/ACTD dossiers, COA, FSC, COPP, WHO-GMP status and exporter recognition should be claimed only when current documentary evidence is available. Export to specific countries cannot be presumed.
Q: What strength is confirmed?
A: Nelfinavir IP 250 mg per tablet, as nelfinavir mesylate.
Q: Does nelfinavir prevent HIV infection?
A: No. It is a treatment medicine used with other antiretrovirals; it is not PrEP or an HIV cure.
Q: Is food important?
A: Food increases nelfinavir absorption; follow the approved product instructions and prescribing advice.
Q: Can it interact with other medicines?
A: Yes. Important CYP-mediated interactions can make certain combinations unsafe. A clinician or pharmacist should check the full medication list.
Use only under specialist prescription as part of a complete antiretroviral regimen. Dosing depends on the approved label, patient age, other medicines, resistance profile and clinical circumstances. Nelfinavir is generally administered with food. Do not start, change, interrupt or substitute HIV medicines without medical guidance; missed or inconsistent doses can contribute to resistance. The supplied historical adult and pediatric schedules are not universal current treatment instructions.
Common adverse effects include diarrhea, nausea and abdominal discomfort. Serious concerns include drug–drug interactions, liver problems, hyperglycemia or new-onset diabetes, lipid changes and increased bleeding in people with hemophilia. Review pregnancy, liver disease, other medicines and relevant monitoring requirements with the treating clinician. Seek urgent medical assessment for severe symptoms or suspected serious reactions.
Keep tablets in their original labeled packaging, protected from excessive heat and moisture, and out of reach of children. Follow the registered product label for temperature and handling; a specific below-25°C limit or desiccant-containing bottle must not be assumed without approved packaging specifications.